Biomarker ID | 1571 |
PMID | 31059955 |
Year | 2019 |
Biomarker | Osteopontin (OPN) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | increased with decreased BRFS |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.38 (95% CI: 1.06- 5.34) |
Effect on Pathways | Pathway include: Integrin Pathway; ERK Signaling; Toll-like Receptor Signaling Pathway; ECM-receptor interaction; Focal Adhesion |
Experiment | Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival |
Type of Biomarker | Prognostic |
Cohort | atients entered into a phase 3 randomised controlled trial of patients receiving EBRT (external beam radiotherapy) or EBRT (n=108) + HDR-BTb (n=110) (high-dose-rate brachytherapy boost). 204 samples were available after immunohistochemistry |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p < 0.036 |
Method Used | Immunohistochemistry |
Clinical | Yes |
Remarks | NA |
Clinical Trial Number | ISRCTN NO: ISRCTN98241100 |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |